Hello @savomic, Welcome to Connect. While we wait wait for others to share their experience, I thought I would share a couple of articles for members not familiar with Distal Acquired Demyelinating Symetric with the M protein (DADS-M).

----- " The pathology of anti-MAG positive DADS, involves deposits of IgM and complement, with splitting of myelin lamellae resulting in demyelination and conduction block. The response to treatment in DADS with paraproteinemia (DADS-M) to the first line agents effective in CIDP is suboptimal (1, 8). Initial reports demonstrated a 30% response rate with minimal subjective improvement in patients with DADS-M while patients with DADS-I or CIDP had nearly 70–95% objective improvement with conventional IMT (6). About 70% of patients with DADS-M in this cohort had anti-MAG antibody positivity, confounding the results as those with anti-MAG antibody do not respond well to first-line CIDP treatments."
-- Treatment Approaches for Atypical CIDP:
https://www.frontiersin.org/articles/10.3389/fneur.2021.653734/full
----- "The presence of MAG antibodies is often linked to a rare demyelinating neuropathy with poor treatment response known as distal acquired demyelinating sensory (DADS) neuropathy. In some cases, reaching correct diagnosis through clinical and electrophysiological evaluation alone can be difficult due to overlapping features, or when patient evaluation occurs later in the disease course. Incorporating MAG antibody testing into the diagnostic workup can help identify the correct diagnosis and exclude patients with treatable immune-mediated neuropathies."
-- MAG - Insights - Mayo Clinic Laboratories:
https://news.mayocliniclabs.com/neurology/autoimmune-neurology/neuropathy/demyelinating-neuropathies/mag/
How are the Rituximab treatments working so far?